Treatment Time Research Articles

Clinical and immunophenotype correlating with response to immunotherapy in paediatric patients with primary liver carcinoma. A case series

Paediatric hepatocellular carcinomas (HCC) traditionally arise in the context of a normal structural and functional liver and carry a dismal prognosis. While chemotherapy is the frontline standard, there is emerging interest in the study of immunotherapies for paediatric patients with relapsed/refractory disease. There is limited data to support whether immunotherapies will be of utility in this patient population. Six paediatric patients (median age:16 years, range: 12-17at the time of treatment) with advanced hepatocellular neosplams, either conventional hepatocellular or fibrolamellar carcinoma, were treated with immunotherapy. Patients were consented to institutional genomic profiling and biobanking protocols. Baseline samples and serial tissue samples, when available, were evaluated for somatic mutation rate, actionable gene mutations, and pan-immune bulk RNA expression profiling. Results were correlated with clinical course. Three patients responded to checkpoint inhibition: one achieved a complete, durable response and the other two, prolonged stable disease. Three additional patients progressed. Diagnostic tissue from the complete responder demonstrated a higher relative mutational burden and robust immune infiltrate. Pre-treatment samples from the three responders demonstrated decreased expression of genes associated with T-cell dysfunction. A subset of patients with primary paediatric hepatocellular tumours will respond to immunotherapy. Immunotherapies are currently under prospective study for relapsed/refractory liver tumours in paediatric patients. Results from this report support the prospective collection of serial serum and tissue samples which may further identify genomic and immunophenotypic patterns predictive of response. This work was supported by Philanthropic funds (Pan Mass Challenge, Team Angus and Team Perspective).

New molecules of importance in the prevention and treatment of acne: A systematic patent review (2016-2020).

Acne is a highly prevalent disease that mainly affects the pilosebaceous units associated with sebaceous glands, causing inflammatory skin lesions and affecting the self-esteem, mental health, and quality of life of those who suffer from this disease. Different treatments exist today to prevent, reduce, and improve symptoms; however, over the years, there have been problems with bacterial resistance and slight effectiveness with prolonged use. The purpose of this article is based on the review of patents of new products of principal topical administration for the treatment of acne in recent years 2016-2020, to evaluate and analyze novel synthetic molecules and semi-synthetics with potential therapeutic and preventive in the acne treatment. A systematic review of patents was conducted through the official database of the European Patent Office - Espacenet, where the search focused on the keywords: "acne and bacteria" in the title or abstract. Only patents granted between the years 2016-2020 were included, with products having molecules with a synthetic and semi-synthetic origin, without considering natural, biological products or those used as diagnostic means. A total of 19 patents were selected, most with principally antimicrobial and anti-inflammatory action, where the reduction in the appearance of resistance by C. acnes is verified, and its action is complemented by inhibiting the different pathophysiological mechanisms that lead to the worsening of the disease. Novel approaches in the treatment and prevention of acne, mainly topically, are focused on the reduction of bacterial resistance and irritation compared to current treatments. The use of combined formulations provides better results with additional benefits, improving treatment times and patient adherence.

Evaluation of treatment of methicillin-resistant Staphylococcus aureus biofilms with intermittent electrochemically generated H2O2 or HOCl.

Chronic wound infections can be difficult to treat and may lead to impaired healing and worsened patient outcomes. Novel treatment strategies are needed. This study evaluated the effects of intermittently produced hydrogen peroxide (H2O2) and hypochlorous acid (HOCl), generated via an electrochemical bandage (e-bandage), against methicillin-resistant Staphylococcus aureus biofilms in an agar membrane biofilm model. By changing the working electrode potential, the e-bandage generated either HOCl (1.5 VAg/AgCl) or H2O2 (-0.6 VAg/AgCl). The degree of biocidal activity of intermittent treatment with HOCl and H2O2 correlated with HOCl treatment time; HOCl treatment durations of 0, 1.5, 3, 4.5, and 6 hours (with the rest of the 6-hour total treatment time devoted to H2O2 generation) resulted in mean biofilm reductions of 1.36 ± 0.2, 2.22 ± 0.16, 3.46 ± 0.38, 4.63 ± 0.74, and 7.66 ± 0.5 log CFU/cm2, respectively, vs. non-polarized controls, respectively. However, application of H2O2 immediately after HOCl treatment was detrimental to biofilm removal. For example, 3 hours HOCl treatment followed by 3 hours H2O2 resulted in a 1.90 ± 0.84 log CFU/cm2 lower mean biofilm reduction than 3 hours HOCl treatment followed by 3 hours non-polarization. HOCl generated over 3 hours exhibited biocidal activity for at least 7.5 hours after e-bandage operation ceased; 3 hours of HOCl generation followed by 7.5 hours of non-polarization resulted in a biofilm cell reduction of 7.92 ± 0.12 log CFU/cm2 vs. non-polarized controls. Finally, intermittent treatment with HOCl (i.e., interspersed with periods of e-bandage non-polarization) for various intervals showed similar effects (approximately 6 log CFU/cm2 reduction vs. non-polarized control) to continuous treatment with HOCl for 3 hours, followed by 3 hours of non-polarization. These findings suggest that timing and sequencing of HOCl and H2O2 treatments are crucial for maximizing biofilm control when using an e-bandage strategy.

Manual and ventilator hyperinflation parameters used by intensive care physiotherapists in Sri Lanka: An online survey.

Hyperinflation is a common procedure to clear secretion, increase lung compliance and enhance oxygenation in mechanically ventilated patients. Hyperinflation can be provided as manual hyperinflation (MHI) or ventilator hyperinflation (VHI), where outcomes depend upon the methods of application. Hence it is crucial to assess the application of techniques employed in Sri Lanka due to observed variations from recommended practices. This study is aimed to evaluate the application and parameters used for MHI and VHI by physiotherapists in intensive care units (ICUs) in Sri Lanka. An online survey was conducted among physiotherapists who are working in ICUs in Sri Lanka using WhatsApp groups and other social media platforms. A total of 96 physiotherapists responded. The survey comprised of three sections to obtain information about socio-demographic data, MHI practices and VHI practices. Most of the respondents (47%) worked in general hospitals and 74% of participants had a bachelor's degree in physiotherapy; 31.3% had 3-6 years of experience; 93.8% used hyperinflation, and 78.9% used MHI. MHI was performed routinely and as needed to treat low oxygen levels, abnormal breath sounds, and per physician orders while avoiding contraindications. Self-inflation bags are frequently used for MHI (40.6%). Only a few participants (26%) used a manometer or tracked PIP. In addition to the supine position, some participants (37.5%) used the side-lying position. Most physiotherapists followed the recommended MHI technique: slow squeeze (57.3%), inspiratory pause (45.8%), and quick release (70.8%). VHI was practised by 19.8%, with medical approval and it was frequently performed by medical staff compared to physiotherapists. Treatment time, number of breaths, and patient positioning varied, and parameters were not well-defined. The study found that MHI was not applied with the recommended PIP, and VHI parameters were not identified. The study indicates a need to educate physiotherapists about current VHI and MHI practice guidelines.

Preparation and properties of asymmetric inverse opal-like microfiltration membranes

Most types of commercially available MF membranes suffer limited separation performances due to huge deviations in pore size and low porosity. In view of this, a new and facile assembly strategy was proposed to prepare an asymmetric inverse opal (IO) like microfiltration (MF) membrane with ordered pore structure, high porosity and large water flux, which is a composite of a disordered layer with three-dimensional pore structures made by dissolved N, N-dimethylformamide (DMF) and an ordered layer with uniform pore size by using a sacrificial template method. The effects of SiO2 microsphere size and DMF treatment on the structure and properties have been investigated. Different DMF treatment times can significantly change the asymmetric structure distribution of MF membrane and further affect the permeability. The water flux of the asymmetric membrane increases with the DMF infiltration time. Based on the SiO2 microsphere template size of 494 nm and the DMF treatment time of 90 s, the porosity and pure water flux can reach 78 % and 1810 L/m2h, respectively. The membrane retains the IO-like structure layer with uniform pore size, and features excellent retention (almost 100 %) for SiO2 microspheres, indicating the great potential of asymmetric IO-like MF membranes for membrane separation applications.

Economic aspects of long-term left ventricular assist device treatment for chronic heart failure.

Technological advances and the current shortage of donor organs have contributed to an increase in the number of left ventricular assist device (LVAD) implantations in patients with end-stage heart failure. Demographic change and medical progress might raise the number of these patients, resulting in a further increase in the number of LVAD implantations. The aim of this study was to evaluate the long-term costs of LVAD therapy and identify diagnoses resulting in expensive stays. In this retrospective analysis of prospectively collected data, all patients after implantation of a second- or third-generation LVAD by 31 March 2022 were included. In addition to demographic and survival data, revenues and case mix points were determined for each patient. Of the 163 patients included, 75.5% were male. The mean age at LVAD implantation was 52±14years. The mean survival was 1458±127days. During follow-up, the total inpatient treatment time per patient was 70±87days. The average duration of outpatient treatment was 55.1%, based on the total duration of support. The average revenue per patient for the implant stay was $193192.35±$111801.29, for inpatient readmissions $52068.96±$116630.00, and for outpatient care $53195.94±$62363.53. LVAD implantation in patients with end-stage heart failure leads to improved survival but a significant increase in treatment costs. Further multi-centre studies are necessary in order to be able to assess the effects of long-term LVAD treatment on the healthcare system.

Evaluation of anti-diabetic potential of Syzygium cumini seed (SCS) powder infused tortilla as therapeutic diet to mitigate hyperglycemia

Diabetes mellitus, a chronic metabolic disorder, is characterized by hyperglycemia. Current therapies to cope up the disease are inadequate to provide instant glycemic control resulting in severe health damage. In current study, Syzygium cumini seed (SCS) powder supplemented wheat tortillas were evaluated qualitatively and quantitatively to regulate the blood glucose levels in diabetic patients. For this purpose, wheat flour was blended with SCS powder at different treatment levels (2%, 4% and 6%). All treatments (T1 – T3) were subjected to proximate analysis, rheological attributes and sensory evaluation to get most acceptable supplementation. Results of such studies revealed that T1 treatment (2% CSC) was found to be the most suitable one, showing paramount results for rheological attributes (Final viscosity: 1803.02±8.84 mPa.s; Peak viscosity: 1597.3±9.99 mPa.s), proximate analysis (Moisture content: 25.82±1.10 %, Ash content: 2.19±0.08%, Fiber content: 1.22±0.08%) and sensory features (Overall acceptability: 8.0±0.07). Tortillas made by such optimized blending level (2% CSC), when applied to a given set of diabetic patients, exhibited remarkable results by giving a significant decrease (206.17±6.01 mg/dL at day1 while 180.41±5.08 mg/dL at day21) in blood glucose level upon increasing time of treatment. Thus, Syzygium cumini seeds can be effectively blended in various food products to control diabetes and other related diseases.

Evaluation of the Treatment Duration of Japanese Patients With Pancreatic Cancer in a Real-World Setting Using a Large Hospital Claims Database: The SUISEI Study.

To clarify the treatment reality of pancreatic cancer in Japan, focusing on treatment duration and time to death. We retrospectively analyzed Japanese hospital claims data for patients diagnosed with pancreatic cancer between April 2009 and October 2018 to investigate treatment patterns, duration of first-line chemotherapy, and time to death. Of 81,185 eligible patients, 54.2% were male, the mean age was 71.7 years, and 23.3% (n = 18,884) received chemotherapy as primary treatment. The median treatment duration was 14.1 weeks for the 6.7% of patients who received oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX; recommended first-line regimen) and 16.9 weeks for the 30.2% of patients who received gemcitabine plus nab-paclitaxel (GEM + nab-PTX). Time to death for patients who received FOLFIRINOX or GEM + nab-PTX was similar (15.4 and 14.8 months, respectively). The duration of first-line chemotherapy regimens tended to increase annually for both regimens. The time to death for all first-line chemotherapy regimens also increased annually. This study revealed the treatment reality of pancreatic cancer in the real-world Japanese setting. Treatment duration and time to death tended to increase over time and did not differ numerically between FOLFIRINOX and GEM + nab-PTX.

Patient-related decisional regret: An evolutionary concept analysis.

Health-related decision-making is a complex process given the variability of treatment options, conflicting treatment plans, time constraints and variable outcomes. This complexity may result in patients experiencing decisional regret following decision-making. Nonetheless, literature on decisional regret in the healthcare context indicates inconsistent characterization and operationalization of this concept. To conceptually define the phenomenon of decisional regret and synthesize the state of science on patients' experiences with decisional regret. A concept analysis. Rodgers' evolutionary method guided the conceptualization of this review. An interdisciplinary literature search was conducted from 2003 until 2023 using five databases, PubMed, CINAHL, Embase, PsycINFO and Web of Science. The search informed how the concept manifested across health-related literature. We used PRISMA-ScR checklist to guide the reporting of this review. Based on the analysis of 25 included articles, a conceptual definition of decisional regret was proposed. Three defining attributes underscored the negative cognitive-emotional nature of this concept, post-decisional experience relating to the decision-making process, treatment option and/or treatment outcome and an immediate or delayed occurrence. Antecedents preceding decisional regret comprised initial psychological or emotional status, sociodemographic determinants, impaired decision-making process, role regret, conflicting treatment plans and adverse treatment outcomes. Consequences of this concept included positive and negative outcomes influencing quality of life, health expectations, patient-provider relationship and healthcare experience appraisal. A conceptual model was developed to summarize the concept's characteristics. The current knowledge on decisional regret is expected to evolve with further exploration of this concept, particularly for the temporal dimension of regret experience. This review identified research, clinical and policy gaps informing our nursing recommendations for the concept's evolution. This concept analysis examines existing literature and does not require patient-related data collection. The methodological approach does not necessitate collaboration with the public.

Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Preliminary Latin American Experience.

Surgical resection is not always achievable in thyroid cancer patients. Neoadjuvant therapy is rarely used, but recent trends favor multikinase inhibitors or selective tyrosine kinase inhibitors. These aim to reduce tumor volume, enabling previously unfeasible surgeries. Consecutive patients with locally advanced malignant thyroid tumors who received systemic therapies with a neoadjuvant intention were included in this retrospective multicenter case series conducted in five Latin American referral centers. Primary outcomes were pre- versus post-neoadjuvant response evaluations using the Response Evaluation Criteria in Solid Tumors, feasibility of surgery and completeness of resection. Secundary outcomes were mortality and status at last visit. Twenty-seven patients were included in this analysis. Patients with unresectable differentiated thyroid cancer (DTC) or poorly differentiated thyroid cancer (PDTC) received sorafenib (n=6) or lenvatinib (n=12), those with medullary thyroid cancer (MTC) were treated with vandetanib (n=5) or selpercatinib (n=1), and those with anaplastic thyroid cancer (ATC) harboring a BRAF V600E mutation (n=3) received dabrafenib and trametinib. The median patient age was 66 years (range 12-82), and 52% of the patients were female. In patients with PTC and PDTC, the median reduction in the diameter of the primary tumor was 25% (range 0-100%) after a median of 6 months of treatment. Surgical intervention was performed in ten (55%) of the patients. Among these, six patients (60%) achieved R0/R1 resection status. Six patients with MTC had a median reduction in tumor diameter of 24.5% (range 1-49) after a median treatment time of 9.5 months. Only one patient receiving selpercatinib, with a tumoral reduction of 25%, could undergo surgery, resulting in an R2 resection due to extensive mediastinal extension.Three patients with ATC showed a median tumor diameter reduction of 42% (range 6.7-50) after a median treatment time of 2 months. Two patients underwent surgical intervention and achieved R1 and R2 resection, respectively. While neoadjuvant therapy achieved tumoral responses, surgical resection was feasible in 50% of DTC, 33% of ATC, and 16% of MTC patients, with R0/R1 resection in 26% of the cohort, underscoring the need for patient selection and further research in this area.

The study on mechanism of water–rock reaction in shale oil formation rich in alkaline minerals in Mahu Sag by using supercritical CO2

The Mahu Sag of Junggar Basin, China is rich in alkaline minerals. Generally, the water–rock reactions between hydraulic fluid and alkaline minerals during the hydraulic fracturing process will lead to the precipitation of minerals and block the pore or wellbore, thereby affecting the recovery efficiency. Supercritical carbon dioxide (ScCO2) regarded as a fracturing fluid can significantly improve the recovery of shale oil resources, but there is limited research on the reaction of ScCO2 to water and rock in shale samples rich in alkaline minerals. Therefore, ScCO2 treatment experiments were conducted on shale samples rich in alkaline minerals under 80°C and 10 MPa. Before the experiments, X-ray powder diffraction (XRD) was applied to characterise the mineral properties of the three shale samples. In addition, the duration time of ScCO2 treatment was set at 7 and 20 days to observe the treatment time impacts on the pore structure. Scanning electron microscopy (SEM) analysis and the Mann–Whitney U test were conducted before and after ScCO2 treatment. SEM images show the changes in pore structure. Opening pores are observed due to the interaction between the alkaline mineral and ScCO2. The Mann–Whitney U test shows the changes in fracture toughness. The changes in pore structure also play an important role in fracture toughness. This study investigated the ScCO2 impacts on shale samples rich in alkaline minerals and the analysis of changes in pore structure and fracture toughness can provide theoretical and data evidence to enable on-site optimisation of the ScCO2 fracturing scheme.

Enhancing Surface Morphology, Mechanical, and Wettability Properties of PVA/Chitosan/HAp Nanofiber Scaffold through Dielectric Barrier Discharge Plasma Treatment

Abstract Dielectric barrier discharge (DBD) plasma treatment has been widely used for surface functionalization, allowing for precise modification of surface chemistry and morphology. This study investigates the efficacy of DBD plasma treatment in enhancing the surface morphology and wettability of electrospun nanofiber scaffolds composed of polyvinyl alcohol (PVA), chitosan, and hydroxyapatite (HAp), with potential applications in bone tissue engineering. Scanning electron microscopy (SEM) revealed significant alterations in surface morphology after treatment, including a reduction in average fiber diameter and the presence of uneven, damaged, and even broken fibers. Interestingly, the ultimate strength of the nanofibers increased from 1.13 ± 0.05 MPa to 6.99 ± 0.07 MPa despite the decrease in diameter. Contact angle measurements confirmed a remarkable improvement in wettability, with the contact angle decreasing from 39.46° to 7.45° following increasing treatment time. This enhanced wettability suggests improved cell adhesion, potentially leading to more effective bone tissue regeneration.

Exploring the Link Between Exogenous Thyroid Hormones and Dementia Symptoms: A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System.

A growing body of evidence indicates a strong association between exogenous thyroid hormone (ETH) and brain health. Establishing the potential relationship between ETH therapy and dementia symptoms is crucial for patients with thyroid disorders. In this study, we investigate the potential association between ETH therapy and dementia symptoms by exploring the Food and Drug Administration Adverse Event Reporting System (FAERS) database. Disproportionality analysis (DPA) was conducted using postmarketing data from the FAERS repository (Q1 2004 to Q4 2023). Cases of dementia symptoms associated with ETH therapy were identified and analyzed through DPA using reporting odds ratios and information component methods. Dose and time-to-onset analyses were performed to assess the association between ETH therapy and dementia symptoms. A total of 9889 cases of ETH-associated symptoms were identified in the FAERS database. Dementia accounted for a consistent proportion of adverse drug reactions each year (3.4%-6.3%). The DPA indicated an association between ETH therapy and dementia symptoms, which remained significant even across sex, age, and indications. The median time-to-onset of dementia symptoms was 7.5 days, and the median treatment time was 40.5 days. No significant dose-response relationship was observed. This study provides evidence for a link between ETH therapy and dementia. Clinicians are therefore advised to exercise vigilance, conduct comprehensive monitoring, and consider individualized dosing to mitigate potential reactions to ETH drug administration.

Investigation on the treatment of empagliflozin in glycogen storage disease type Ib

Objective: To investigate the safety, efficacy and effective dose of empagliflozin in the treatment of glycogen storage disease type Ⅰb (GSD Ⅰb). Method: This was a cross sectional study. A total of 28 children with GSDⅠb who started oral empagliflozin treatment from January 2021 to June 2023 in the WeChat group of patients with glycogen storage disease were selected as the study objects. Clinical data such as general situation, current situation of medication and adverse reactions of the children were collected through questionnaires from June 18 to 30, 2023. The differences of symptoms and laboratory tests before and after empagliflozin treatment were compared by using paired chi-square test and Wilcoxon signed rank sum test. Results: Totally 28 children with GSD Ⅰb were from 12 different provinces, autonomous regions and municipalities in China. There were 14 males and 14 females, Empagliflozin treatment was started at the age of 4.8(2.4, 10.8) years, the time of treatment was 14.5(11.3, 21.5) months, the initial dosage was (0.23±0.11) mg/(kg·d), and the maintenance dosage was (0.28±0.12) mg/(kg·d). Empagliflozin showed positive effects on neutropenia, severity of inflammatory bowel disease like symptoms(Z=-3.70, -2.65, both P<0.05), The proportion of recurrent oral ulcers, recurrent bacterial infections and anemia was significantly lower than that before medication 18% (5/28) vs. (46% (13/28), 14% (4/28) vs. 46% (13/28), 21% (6/28) vs. 46% (13/28), χ²=4.05, 5.26, 3.05, all P<0.05). GCSF was once used in 5 children with GSD Ⅰb, all of them had completely stopped GCSF after empagliflozin treatment. The most common adverse events during empagliflozin treatment were hypoglycemia (5 children) and urinary infection (3 children). All 28 patients had no serious adverse reactions. Conclusions: Empagliflozin can increase the neutrophil count of children with GSD Ⅰb, and had a favorable effect on symptoms such as recurrent oral ulcers, and recurrent infection. The common adverse events during empagliflozin treatment were hypoglycemia and urinary infection.

Identifying the Potential Apoptotic Metabolites in Postmortem Beef Muscle by Targeted Metabolomics.

Apoptotic cells may release specific metabolites to act as messengers during the apoptotic process. This study represents the first attempt to identify potential apoptotic metabolites in postmortem muscle. Ninety potential apoptotic metabolites in beef were selected and analyzed through targeted metabolomics, with 84 of them exhibiting significant differences over the postmortem time. Following the addition of the mitochondria-targeted antiapoptotic agent mitoquinone to postmortem muscle, metabolomic analysis revealed that 73 apoptotic metabolites still underwent significant changes, even against the backdrop of altered apoptosis. Of these 73 apoptotic metabolites, 54 exhibited similar trends at various treatment times with adding mitoquinone, including lipids (6), amino acids (27), nucleosides (11), and carbohydrate and energy metabolism (10). Mitoquinone significantly reduced the levels of most apoptotic metabolites, and inhibition of apoptosis resulted in a significant decrease in the levels of numerous apoptotic metabolites. Consequently, these apoptotic metabolites are considered complementary to apoptosis in postmortem muscle, with their increased levels potentially promoting apoptosis. Noteworthy apoptotic metabolites, such as glycerol 3-phosphate, serine, AMP, ATP, GMP, and creatine, were identified as active signaling molecules that attract and recruit phagocytes during apoptosis, assisting in recognizing apoptotic cells by phagocytes. This study provides, for the first time, insights into potential apoptotic metabolites in postmortem muscle, contributing to a better understanding of meat biochemistry.

Advansync in management of class II malocclusion: A systematic review

Class II malocclusions are of interest to practising orthodontists since they constitute a significant percentage of the cases they treat. In individuals with Class II malocclusions, there is an anteroposterior discrepancy between the maxillary and mandibular dentitions, which is usually accompanied by a skeletal discrepancy. In such malocclusions, a functional appliance (myofunctional or fixed functional) is chosen as a treatment method depending on the severity and need of the particular case. This systematic review aims to evaluate the dental-alveolar, skeletal and soft tissue changes with the use of Advansync™ (A Class II corrector/ fixed functional appliance) in the treatment of Class II malocclusion. A literature search was done on Pubmed, EbscoHost , Google Scholar, Science Direct. This was conducted by two reviewers independently and any conflicts in results were managed through discussion. A Risk of Bias was done for the final articles included in the study. A total of 3,099 records were identified while searching through the database based on Mesh terms and search strategies. Based on the inclusion and exclusion criteria’s the total articles which were eligible for the systematic review were six. As the study was specific in terms of age and gender there was a high risk of selection bias but low risk of reporting bias.Out of the 6 studies, 5 had a low risk of bias and based on their cumulative findings, the effectiveness of Advansync is similar to those of other Class II correctors. The advantage of Advansync over other correctors is that the appliance saves treatment time and can be incorporated from the second month of treatment thereby shortening the duration of treatment.Fixed Class II correctors are used widely in Orthodontics. The selection of the appropriate appliance for the patient is the need of the hour. Thus, this systematic review gives us an insight on the use of Advansync in Class II correction.

Hardness Testing and Scratch Testing with Heat Treatment Time for Electroless Ni-P Plating on Aluminum Alloy Die Casting

Hardness Testing and Scratch Testing with Heat Treatment Time for Electroless Ni-P Plating on Aluminum Alloy Die Casting

Innovating Prosthodontic Rehabilitation: A Streamlined Two-Step Technique for Mobile Denture Fabrication

This manuscript introduces a novel two-step technique for fabricating mobile dentures post-extraction to streamline prosthodontic rehabilitation. The study utilizes various materials, including dental polymers, metals, ceramics, and composite materials, each chosen for their unique properties that contribute to the final prosthesis’s functionality, durability, and esthetics. The detailed procedure involves an initial occlusal registration immediately following tooth extraction, capturing precise occlusal relationships and a comprehensive dental impression. This approach reduces clinical visits and leverages optimal alveolar ridge morphology. The expected results highlight the efficiency of the technique, reducing treatment time without compromising quality and potentially improving patient satisfaction and prosthodontic outcomes. This innovative method conclusively promises rapid, efficient, and patient-centered dental rehabilitation, emphasizing the need for future research to validate its effectiveness and explore long-term outcomes.

Physiological and transcriptomic analyses provide preliminary insights into the autotoxicity of Lilium brownii

Physiological and transcriptomic analyses provide preliminary insights into the autotoxicity of Lilium brownii

Optimization of bromocresol green degradation using ozone micro bubbles: response surface analysis and techno-commercial aspects of a 75 kL/day scale-up plant

Degradation of bromocresol green in alcohol-water solution using ozone micron sized bubbles is reported. A high speed impeller is used to generate micro bubbles of ozone in liquid while ozone is generated using a commercial ozone generator. A 3-level-3-factor Box–Behnken experimental design is used to statistically identify relative importance of the operating parameters studied namely impeller speed, initial concentration of dye and treatment time. Ozone dosage is kept fixed at 4 g/h. Impeller speed is found to be the most dominant factor according to Analysis of Variance (ANOVA) calculations. Kinetics for degradation of bromocresol green in solution is also reported. A second order kinetics is seen to fit the experimental (concentration–time) data, corresponding value of rate constant being 0.0153 L/mg-s. Based on the laboratory scale data a detailed techno-commercial analysis of a scaled up (75 kL/day) plant for ozone based degradation of bromocresol is presented. All relevant economic indicators pertaining to the scaled up plant are reported. A specific treatment cost of Rs. 100/m3 of treated water yields a return on investment (ROI) of 68.77 and discounted payback period of 5 years.